Tagged with M

Cannabis Following the death penalty handed to Muhammad Lukman, a 29-year old man who was convicted of possessing, processing and distributing medicinal cannabis oil, public outcry has caused Malaysian officials to reconsider the punishment.   Muhammad Lukman was arrested in 2015 for possessing 3.1 litres of cannabis oil, 279 g of compressed cannabis and 1.4 kg of…

regulation The stakes are high, and the outcome is uncertain in one of the largest Pharma M&A deals ever. Takeda’s proposed acquisition of Shire seems to have it all: The combined entity becoming one of the largest global Pharma groups, enabling Takeda to become a truly global operation and allowing Shire’s…

Turkey Prof. Dr. Sabahattin Aydın, Rector of Medipol University, chairman of the Executive Council of TUSAP Healthcare Platform, former executive board member of the World Health Organization (WHO), former deputy undersecretary (2003-2010) at the Ministry of Health of Turkey, and one of the most respected healthcare leaders in Turkey, provides insights…

UK For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions including HR, Tech Ops and Commercial Operations in Slough, near London. With ten percent annual growth to reach GBP 80…

UK Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of Amgen company culture.   Everyone tells you how complicated the UK market is and that is true – it’s one…

Turkey Fikret Baltaoglu of Laboratoires Expanscience, reveals all on the company’s recent expansion into the Turkish market after acquiring its distribution partner. He also sheds light on how the Turkish healthcare system could benefit from critical products which are not often considered to have strong ties to preventative care.   Can…

Hong Kong Wolfgang Niedermark of GIC in Hong Kong, part of the AHK network of German Chambers of Commerce worldwide assesses the business relationship between Germany and Asia and how Hong Kong compares to its regional competitors as an investment destination What is your assessment of the business relationship between Germany and…

Turkey Hasan Ulusoy, chairman of Nobel Ilac, elaborates on his company’s tremendous successes in Turkey and how they have differentiated themselves through early investment in biotechnology and firmly grasping international opportunities. Ulusoy also highlight’s Nobel’s vision for 2023 and their global ambitions. Alongside hospital products, biologicals are the next big opportunity…

Hong Kong Matthew Man, CEO of Hong Kong cold chain monitoring technology specialist Myndar, expounds on the company’s formation, its differentiating factors, and countering resistance to new innovations in the healthcare sector.   How did you identify the niche in the market for your cold chain monitoring technologies? I founded Myndar back…

Algeria Farid Benhamdine discusses the changing role of the hospital pharmacist, and the potential for a new pharmaceutical agency in Algeria. He reveals the issues this is required to solve, and the benefits he sees this bringing to the system.   The role of the pharmacist in a healthcare ecosystem is…

Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…

UK There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario. Different…